NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free OCX Stock Alerts $2.66 -0.12 (-4.32%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.63▼$2.8050-Day Range$2.44▼$3.0752-Week Range$2.08▼$5.88Volume15,346 shsAverage Volume162,230 shsMarket Capitalization$22.00 millionP/E RatioN/ADividend YieldN/APrice Target$4.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OncoCyte alerts: Email Address OncoCyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside52.7% Upside$4.06 Price TargetShort InterestBearish3.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$7.18 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector743rd out of 904 stocksDiagnostic Substances Industry9th out of 13 stocks 3.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.08% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in OncoCyte has recently increased by 30.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for OncoCyte this week, compared to 1 article on an average week.Search Interest6 people have searched for OCX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,176,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About OncoCyte Stock (NASDAQ:OCX)OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesApril 16, 2024 | insidertrades.comOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in StockApril 30, 2024 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.comMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 25, 2024 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLCApril 24, 2024 | markets.businessinsider.comStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyApril 22, 2024 | msn.comBuffett Grabs More of This Stock, Plus Other Notable Insider BuyingApril 13, 2024 | seekingalpha.comOncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptApril 13, 2024 | finance.yahoo.comQ4 2023 OncoCyte Corp Earnings CallMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 12, 2024 | investorplace.comOCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023April 12, 2024 | msn.comTop 3 Health Care Stocks That May Collapse In Q2April 12, 2024 | finanznachrichten.deOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Digest Big Bank EarningsApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsApril 12, 2024 | msn.comOncocyte announces $15.8 mln private placement of securitiesApril 12, 2024 | globenewswire.comOncocyte Reports Full Year 2023 Financial ResultsApril 11, 2024 | globenewswire.comOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesApril 11, 2024 | globenewswire.comOncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 11, 2024 | markets.businessinsider.comHere's what Wall Street expects from Oncocyte's earningsApril 9, 2024 | globenewswire.comOncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsFebruary 29, 2024 | msn.comNeuroBo stock jumps 14% on weight-loss drug updateFebruary 24, 2024 | benzinga.comOncoCyte Stock (NASDAQ:OCX), Short Interest ReportJanuary 16, 2024 | finance.yahoo.comOncocyte to Present at the Sequire Investor Summit in Puerto RicoJanuary 7, 2024 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on OncoCyte (OCX)December 11, 2023 | benzinga.comOncoCyte Stock (NASDAQ:OCX) Dividends: History, Yield and DatesDecember 6, 2023 | finance.yahoo.comOncocyte Begins FDA Submissions Process for VitaGraft Transplant AssaysNovember 18, 2023 | morningstar.comOncoCyte Corp OCXSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/05/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees75Year FoundedN/APrice Target and Rating Average Stock Price Target$4.06 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+52.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,780,000.00 Net Margins-1,890.62% Pretax Margin-1,653.69% Return on Equity-96.30% Return on Assets-41.12% Debt Debt-to-Equity RatioN/A Current Ratio1.49 Quick Ratio1.49 Sales & Book Value Annual Sales$1.50 million Price / Sales14.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book1.07Miscellaneous Outstanding Shares8,270,000Free Float8,113,000Market Cap$22.00 million OptionableNo Data Beta0.80 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 41)President, CEO & Director Comp: $373.2kMr. James Liu (Age 28)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $192.48kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Peter HongVP, General Counsel & SecretaryMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 71)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. Ms. Sara RiordanDirector of Medical EducationMore ExecutivesKey CompetitorsCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBDURECTNASDAQ:DRRXAchilles TherapeuticsNASDAQ:ACHLBiomericaNASDAQ:BMRAView All CompetitorsInsiders & InstitutionsBroadwood Partners, L.P.Bought 2,420,000 shares on 4/11/2024Total: $7.07 M ($2.92/share)Andrew ArnoBought 33,898 shares on 4/11/2024Total: $99,999.10 ($2.95/share)Josh RiggsBought 3,390 shares on 4/11/2024Total: $10,000.50 ($2.95/share)Pura Vida Investments LLCSold 71,191 shares on 2/13/2024Ownership: 7.106%Alfred D KingsleyBought 1,500 shares on 6/14/2023Total: $6,300.00 ($4.20/share)View All Insider TransactionsView All Institutional Transactions OCX Stock Analysis - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price target for 2024? 4 equities research analysts have issued 1-year target prices for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's share price to reach $4.06 in the next year. This suggests a possible upside of 52.7% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2024? OncoCyte's stock was trading at $2.50 at the beginning of the year. Since then, OCX stock has increased by 6.4% and is now trading at $2.66. View the best growth stocks for 2024 here. Are investors shorting OncoCyte? OncoCyte saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 233,100 shares, an increase of 30.2% from the March 31st total of 179,100 shares. Based on an average daily trading volume, of 54,900 shares, the days-to-cover ratio is presently 4.2 days. Approximately 3.1% of the company's stock are sold short. View OncoCyte's Short Interest. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($3.00) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by $0.60. The firm earned $0.98 million during the quarter, compared to the consensus estimate of $3.20 million. OncoCyte had a negative trailing twelve-month return on equity of 96.30% and a negative net margin of 1,890.62%. When did OncoCyte's stock split? OncoCyte shares reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.